Publications

Editorials

Cerebrospinal fluid levels of alpha-synuclein in Parkinson’s disease: Another long and winding road.
Markopoulou K, Compta Y.
Parkinsonism Relat Disord. 2018 Apr;49:1-3. doi: 10.1016/j.parkreldis.2018.02.035.

Thoughts on fatigue in Parkinson’s disease (and other disorders).
Friedman JH.
Eur J Neurol. 2017 Jan;24(1):5-6.


β-Amyloid in CSF. A window into Parkinson disease dementia.
Siderowf A, Logroscino G.
Neurology. 2014 Apr 18.


Can Mild Cognitive Impairment in Parkinson Disease Predict the Development of Dementia?
Copeland BJ, Schiess MC.
JAMA Neurol. 2013 Mar 25:1-3.


The Riddle of Psychiatric Disorders in Parkinson’s Disease: From Phenomenology to Treatment.
Starkstein SE.
Am J Geriatr Psychiatry 20:2, February 2012


Motor deficits associated with changes in β-amyloid in Parkinson’s disease.
Halliday GM.
J Neurol Neurosurg Psychiatry. 2012 Nov 9.


Is fatigue in early Parkinson’s disease a minor inconvenience or major distress? The answer is ‘yes’!
Friedman JH.
Eur J Neurol. 2012 Jul;19(7):931-2.


Not all that goes «bump in the night» is RLS: Leg motor restlessness in PD.
Arnulf I, Morgan J.
Neurology. 2011 Nov;77(22):1936-1937.


Extending MCI beyond Alzheimer disease.
Paulsen JS, Duff K.
Neurology. 2009 Mar;72(13):1116-1117.


Neuropsychiatric disorders in early untreated Parkinson’s disease.
Starkstein SE.
J Neurol Neurosurg Psychiatry. 2009 Aug;80(8).


Publications

2018

Inflammation and fatigue in early, untreated Parkinson’s Disease.
Herlofson K, Heijnen CJ, Lange J, Alves G, Tysnes OB, Friedman JH, Fagundes CP.
Acta Neurol Scand. 2018 Nov;138(5):394-399. doi: 10.1111/ane.12977. Epub 2018 Jun 26.
PMID: 29947088


Rare genetic variation in mitochondrial pathways influences the risk for Parkinson’s disease.
Gaare JJ, Nido GS, Sztromwasser P, Knappskog PM, Dahl O, Lund-Johansen M, Maple-Grødem J, Alves G, Tysnes OB, Johansson S, Haugarvoll K, Tzoulis C.
Mov Disord. 2018 Oct;33(10):1591-1600. doi: 10.1002/mds.64. Epub 2018 Sep 5.
PMID: 30256453


Association of glucocerebrosidase polymorphisms and mutations with dementia in incident Parkinson’s disease.
Lunde KA, Chung J, Dalen I, Pedersen KF, Linder J, Domellöf ME, Elgh E, Macleod AD, Tzoulis C, Larsen JP, Tysnes OB, Forsgren L, Counsell CE, Alves G, Maple-Grødem J.
Alzheimers Dement. 2018 Oct;14(10):1293-1301. doi: 10.1016/j.jalz.2018.04.006. Epub 2018 May 21.
PMID: 29792872


Is psychosis associated with impulse control disorders in Parkinson’s disease?
Erga AH, Bjørnestad A, Tysnes OB, Alves G, Pedersen KF.
Parkinsonism Relat Disord. 2018 Aug;53:110-111. doi: 10.1016/j.parkreldis.2018.04.026. Epub 2018 May 2.
PMID: 29735273


Hyposmia in a simple smell test is associated with accelerated cognitive decline in early Parkinson’s disease.
Gjerde KV, Müller B, Skeie GO, Assmus J, Alves G, Tysnes OB.
Acta Neurol Scand. 2018 Jul 30. doi: 10.1111/ane.13003. [Epub ahead of print]
PMID: 30058142


Alzheimer disease associated variants in SORL1 accelerate dementia development in Parkinson disease.
Maple-Grødem J, Chung J, Lunde KA, Tzoulis C, Tysnes OB, Pedersen KF, Alves G.
Neurosci Lett. 2018 Mar 19;674:123-126.
PMID:2956742


Dopaminergic and Opioid Pathways Associated with Impulse Control Disorders in Parkinson’s Disease.
Erga AH, Dalen I, Ushakova A, Chung J, Tzoulis C, Tysnes OB, Alves G, Pedersen KF, Maple-Grødem J.
Front Neurol. 2018 Feb 28;9:109.
PMID:29541058


Evolution of cerebrospinal fluid total α-synuclein in Parkinson’s disease.
Førland MG, Öhrfelt A, Dalen I, Tysnes OB, Blennow K, Zetterberg H, Pedersen KF, Alves G, Lange J.
Parkinsonism Relat Disord. 2018 Apr;49:4-8.
PMID:29409704


No evidence for rare TRAP1 mutations influencing the risk of idiopathic Parkinson’s disease.
Gaare JJ, Nido GS, Sztromwasser P, Knappskog PM, Dahl O, Lund-Johansen M, Alves G, Tysnes OB, Johansson S, Haugarvoll K, Tzoulis C.
Brain. 2018 Jan 24.
PMID: 29373637


Neuronal complex I deficiency occurs throughout the Parkinson’s disease brain, but is not associated with neurodegeneration or mitochondrial DNA damage.
Flønes IH, Fernandez-Vizarra E, Lykouri M, Brakedal B, Skeie GO, Miletic H, Lilleng PK, Alves G, Tysnes OB, Haugarvoll K, Dölle C, Zeviani M, Tzoulis C.
Acta Neuropathol. 2018 Mar;135(3):409-425.
PMID: 29270838


Ultradeep mapping of neuronal mitochondrial deletions in Parkinson’s disease.
Nido GS, Dölle C, Flønes I, Tuppen HA, Alves G, Tysnes OB, Haugarvoll K, Tzoulis C.
Neurobiol Aging. 2018 Mar;63:120-127.
PMID: 29257976


Development and validation of prognostic survival models in newly diagnosed Parkinson’s disease.
Macleod AD, Dalen I, Tysnes OB, Larsen JP, Counsell CE.
Mov Disord. 2018 Jan;33(1):108-116.
PMID: 28976022


2017

The natural history of depressive symptoms in patients with incident Parkinson’s disease: a prospective cohort study.
Larsen JP, Dalen I, Pedersen KF, Tysnes OB.
J Neurol. 2017 Dec;264(12):2401-2408.
PMID: 29032408


The GBA variant E326K is associated with Parkinson’s disease and explains a genome-wide association signal.
Berge-Seidl V, Pihlstrøm L, Maple-Grødem J, Forsgren L, Linder J, Larsen JP, Tysnes OB, Toft M.
Neurosci Lett. 2017 Sep 29;658:48-52.
PMID: 28830825


Clinical milestones in Parkinson’s disease: A 7-year population-based incident cohort study.
Bjornestad, Pedersen, Tysnes OB, Alves G.
Parkinsonism Relat Disord. 2017 May 29. pii: S1353-8020(17)30191-8. doi: 10.1016/j.parkreldis.2017.05.025.


Is fatigue associated with cognitive dysfunction in early Parkinson’s disease?
Kluger BM, Pedersen KF, Tysnes OB, Ongre SO, Øygarden B, Herlofson K.
Parkinsonism Relat Disord. 2017 Feb 7. pii: S1353-8020(17)30040-8. doi: 10.1016/j.parkreldis.2017.02.005.


Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study.
Pedersen KF, Larsen JP, Tysnes OB, Alves G.
Neurology. 2017 Jan 20. pii: 10.1212/WNL.0000000000003634.

2016

Long-term risk of falls in an incident Parkinson’s disease cohort: the Norwegian ParkWest study.
Hiorth YH, Alves G, Larsen JP, Schulz J, Tysnes OB, Pedersen KF.
J Neurol. 2016 Dec 20. doi: 10.1007/s00415-016-8365-z. [Epub ahead of print]
PMID: 28000003


Changes in insomnia subtypes in early Parkinson disease.
Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD.
Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003540.
PMID: 27986876


Impulsive and Compulsive Behaviors in Parkinson Disease: The Norwegian ParkWest Study.
Erga AH, Alves G, Larsen JP, Tysnes OB, Pedersen KF.
J Parkinsons Dis. 2016 Nov 30.
PMID: 27911342


Defective mitochondrial DNA homeostasis in the substantia nigra in Parkinson disease.
Dölle C, Flønes I, Nido GS, Miletic H, Osuagwu N, Kristoffersen S, Lilleng PK, Larsen JP, Tysnes OB, Haugarvoll K, Bindoff LA, Tzoulis C.
Nat Commun. 2016 Nov 22;7:13548. doi: 10.1038/ncomms13548.
PMID: 27874000


Familial aggregation of Parkinson’s disease may affect progression of motor symptoms and dementia.
Gaare JJ, Skeie GO, Tzoulis C, Larsen JP, Tysnes OB.
Mov Disord. 2016 Nov 10. doi: 10.1002/mds.26856.  Review.
PMID: 27862270


Measuring Life Satisfaction in Parkinson’s Disease and Healthy Controls Using the Satisfaction With Life Scale.
Løvereide L, Hagell P.
PLoS One. 2016 Oct 24;11(10):e0163931. doi: 10.1371/journal.pone.0163931.
PMID: 27776131


Fatigue in early Parkinson’s disease: the Norwegian ParkWest study.
Ongre SO, Larsen JP, Tysnes OB, Herlofson K.
Eur J Neurol. 2016 Sep 26. doi: 10.1111/ene.13161.
PMID: 27670392


Loss of independence in early Parkinson disease: A 5-year population-based incident cohort study.
Bjornestad A, Tysnes OB, Larsen JP, Alves G.
Neurology. 2016 Oct 11;87(15):1599-1606.
PMID: 27590290


Validation of a new assay for α-synuclein detection in cerebrospinal fluid.
Førland MG, Öhrfelt A, Oftedal LS, Tysnes OB, Larsen JP, Blennow K, Zetterberg H, Alves G, Lange J.
Clin Chem Lab Med. 2016 Jul 30. pii: /j/cclm.ahead-of-print/cclm-2016-0409/cclm-2016-0409.xml. doi: 10.1515/cclm-2016-0409.
PMID: 27474841


Reliability of Three Disability Scales for Detection of Independence Loss in Parkinson’s Disease.
Bjornestad A, Tysnes OB, Larsen JP, Alves G.
Parkinsons Dis. 2016;2016:1941034. doi: 10.1155/2016/1941034.
PMID: 27213080


Impact of Falls on Physical Activity in People with Parkinson’s Disease.
Hiorth YH, Larsen JP, Lode K, Tysnes OB, Godfrey A, Lord S, Rochester L, Pedersen KF.
J Parkinsons Dis. 2016;6(1):175-82. doi: 10.3233/JPD-150640.
PMID: 26639446


Risk and course of motor complications in a population-based incident Parkinson’s disease cohort.
Bjornestad A, Forsaa EB, Pedersen KF, Tysnes OB, Larsen JP, Alves G.
Parkinsonism Relat Disord. 2016 Jan;22:48-53. doi: 10.1016/j.parkreldis.2015.11.007.
PMID: 26585090


2015

Association of a BACE1 Gene Polymorphism with Parkinson’s Disease in a Norwegian Population.
Lange J, Lunde KA, Sletten C, Møller SG, Tysnes OB, Alves G, Larsen JP, Maple-Grødem J.
Parkinsons Dis. 2015;2015:973298. doi: 10.1155/2015/973298. Epub 2015 Dec 14.
PMID: 26788404


The role of TREM2 R47H as a risk factor for Alzheimer’s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease.
Lill CM, Rengmark A, Pihlstrøm L, Fogh I, Shatunov A, Sleiman PM, Wang LS, Liu T, Lassen CF, Meissner E, Alexopoulos P, Calvo A, Chio A, Dizdar N, Faltraco F, Forsgren L, Kirchheiner J, Kurz A, Larsen JP, Liebsch M, Linder J, Morrison KE, Nissbrandt H, Otto M, Pahnke J, Partch A, Restagno G, Rujescu D, Schnack C, Shaw CE, Shaw PJ, Tumani H, Tysnes OB, Valladares O, Silani V, van den Berg LH, van Rheenen W, Veldink JH, Lindenberger U, Steinhagen-Thiessen E; SLAGEN Consortium, Teipel S, Perneczky R, Hakonarson H, Hampel H, von Arnim CA, Olsen JH, Van Deerlin VM, Al-Chalabi A, Toft M, Ritz B, Bertram L.
Alzheimers Dement. 2015 Apr 30.


Development of excessive daytime sleepiness in early Parkinson disease.
Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD.
Neurology. 2015 Jul 14;85(2):162-8. 


HTRA2 p.G399S in Parkinson disease, essential tremor, and tremulous cervical dystonia.
Tzoulis C, Zayats T, Knappskog PM, Müller B, Larsen JP, Tysnes OB, Bindoff LA, Johansson S, Haugarvoll K.
Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2268.


Fine mapping and resequencing of the PARK16 locus in Parkinson’s disease.
Pihlstrøm L, Rengmark A, Bjørnarå KA, Dizdar N, Fardell C, Forsgren L, Holmberg B, Larsen JP, Linder J, Nissbrandt H, Tysnes OB, Dietrichs E, Toft M.
J Hum Genet. 2015 Jul;60(7):357-62.


2014

The factor structure of the UPDRS motor scores changes during early Parkinson’s disease.
Brakedal B, Tysnes OB, Skeie GO, Larsen JP, Müller B.
Parkinsonism Relat Disord. 2014 Jun;20(6):617-21.


CSF Aβ42 predicts early-onset dementia in Parkinson disease.
Alves G, Lange J, Blennow K, Andreasson U, Førland M, Tysnes OB, Larsen JP, Pedersen KF.
Neurology. 2014 Apr 18.


2013

Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson’s disease.
Müller B, Assmus J, Herlofson K, Larsen JP, Tysnes OB.
Parkinsonism Relat Disord. 2013 Aug 2.


Prognosis of Mild Cognitive Impairment in Early Parkinson Disease: The Norwegian ParkWest Study.
Pedersen KF, Larsen JP, Tysnes OB, Alves G.
JAMA Neurol. 2013 Mar 25:1-7.


Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson’s disease.
Beyer MK, Alves G, Hwang KS, Babakchanian S, Bronnick KS, Chou YY, Dalaker TO, Kurz MW, Larsen JP, Somme JH, Thompson PM, Tysnes OB, Apostolova LG.
Mov Disord. 2013 Mar;28(3):302-10. doi: 10.1002/mds.25282. Epub 2013 Feb 13.


Verbal memory is associated with structural hippocampal changes in newly diagnosed Parkinson’s disease.
Beyer MK, Bronnick KS, Hwang KS, Bergsland N, Tysnes OB, Larsen JP, Thompson PM, Somme JH, Apostolova LG.
J Neurol Neurosurg Psychiatry. 2013 Jan;84(1):23-8.


Supportive evidence for 11 loci from genome-wide association studies in Parkinson’s disease.
Pihlstrøm L, Axelsson G, Bjørnarå KA, Dizdar N, Fardell C, Forsgren L, Holmberg B, Larsen JP, Linder J, Nissbrandt H, Tysnes OB, Ohman E, Dietrichs E, Toft M.
Neurobiol Aging. 2013 Jun;34(6):1708.e7-13.


Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson’s disease.
Alves G, Pedersen KF, Bloem BR, Blennow K, Zetterberg H, Borm GF, Dalaker TO, Beyer MK, Aarsland D, Andreasson U, Lange J, Tysnes OB, Zivadinov R, Larsen JP.
J Neurol Neurosurg Psychiatry. 2013 May;84(5):537-43.


Autonomic symptoms and dopaminergic treatment in de novo Parkinson’s disease.
Müller B, Assmus J, Larsen JP, Haugarvoll K, Skeie GO, Tysnes OB.
Acta Neurol Scand. 2013 Apr;127(4):290-4.23.


Parkinson disease: Associated disorders in the Norwegian population based incident ParkWest study.
Skeie GO, Muller B, Haugarvoll K, Larsen JP, Tysnes OB.
Parkinsonism Relat Disord.2013 Jan;19(1):53-5.


Frequencies of falls and associated features at different stages of Parkinson’s disease.
Hiorth YH, Lode K, Larsen JP.
Eur J Neurol. 2013 Jan;20(1):160-6.


Treatment in early Parkinson’s disease: the Norwegian ParkWest study.
Tveiten OV, Skeie GO, Haugarvoll K, Müller B, Larsen JP, Tysnes OB.
Acta Neurol Scand. 2013 Aug;128(2):107-13.


2012

Number of CAG repeats in POLG1 and its association with Parkinson disease in the Norwegian population.
Balafkan N, Tzoulis C, Müller B, Haugarvoll K, Tysnes OB, Larsen JP, Bindoff LA.
Mitochondrion. 2012 Nov;12(6):640-3.


Psychometric Properties of the Starkstein Apathy Scale in Patients With Early Untreated Parkinson Disease.
Pedersen KF, Alves G, Larsen JP, Tysnes OB, Møller SG, Brønnick K.
Am J Geriatr Psychiatry. 2012 Feb;20(2):142-8.


Subjective sleep problems in patients with early Parkinson’s disease.
Stefansdottir S, Gjerstad MD, Tysnes OB, Larsen JP.
Eur J Neurol. 2012 Dec;19(12):1575-81.


Fatigue in early Parkinson’s disease. Minor inconvenience or major distress?
Herlofson K, Ongre SO, Enger LK, Tysnes OB, Larsen JP.
Eur J Neurol. 2012 Jul;19(7):963-8.


Psychometric Properties of the Starkstein Apathy Scale in Patients With Early Untreated Parkinson Disease.
Pedersen KF, Alves G, Larsen JP, Tysnes OB, Møller SG, Brønnick K.
Am J Geriatr Psychiatry. 2012 Feb;20(2):142-8.


2011
Increased risk of leg motor restlessness but not RLS in early Parkinson disease.
Gjerstad MD, Tysnes OB, Larsen JP.
Neurology. 2011 Nov 29;77(22):1941-6.


Ventricular enlargement and mild cognitive impairment in early Parkinson’s disease.
Dalaker TO, Zivadinov R, Ramasamy DP, Beyer MK, Alves G, Bronnick KS, Tysnes OB, Aarsland D, Larsen JP.
Mov Disord. 2011 Feb 1;26(2):297-301.


Verbal memory in drug-naive, newly diagnosed parkinson’s disease. The retrieval deficit hypothesis revisited.
Brønnick K, Alves G, Aarsland D, Tysnes OB, Larsen JP.
Neuropsychology. 2011 Jan;25(1):114-24.


Autonomic and sensory symptoms and signs in incident, untreated Parkinson’s disease: Frequent but mild.
Müller B, Larsen JP, Wentzel-Larsen T, Skeie GO, Tysnes OB; for The ParkWest Study Group.
Mov Disord. 2011 Jan;26(1):65-72.


2010
Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis.

Aarsland D, Bronnick K, Williams-Gray C, Weintraub D, Marder K, Kulisevsky J, Burn D, Barone P, Pagonabarraga J, Allcock L, Santangelo G, Foltynie T, Janvin C, Larsen JP, Barker RA, Emre M.
Neurology. 2010 Sep 21;75(12):1062-9.


Differential effect of environmental risk factors on postural instability gait difficulties and tremor dominant Parkinson’s disease.
Skeie GO, Muller B, Haugarvoll K, Larsen JP, Tysnes OB.
Mov Disord. 2010 Sep 15;25(12):1847-52.


Are dysautonomic and sensory symptoms present in early Parkinson’s disease?
Tysnes OB, Müller B, Larsen JP.
Acta Neurol Scand Suppl. 2010;(190):72-7.


CSF amyloid-{beta} and tau proteins, and cognitive performance, in early and untreated Parkinson’s Disease: the Norwegian ParkWest study.
Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E.
J Neurol Neurosurg Psychiatry.  2010 Oct;81(10):1080-6.


“The role of APOE alleles in newly diagnosed PD patients in Western Norway. The Norwegian ParkWest study”.
Vefring H, Haugarvoll K, Tysnes OB, Larsen JP, Kurz MW; for the Norwegian ParkWest Study group.
Acta Neurol Scand. 2010 Dec;122(6):438-41.


Gray matter correlations of cognition in incident Parkinson’s disease.
Dalaker TO, Zivadinov R, Larsen JP, Beyer MK, Cox JL, Alves G, Bronnick K, Tysnes OB, Antulov R, Dwyer MG, Aarsland D.
Mov Disord. 2010 Apr 15;25(5):629-33.


Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson’s disease: the Norwegian ParkWest study.
Leiknes I, Tysnes OB, Aarsland D, Larsen JP.
Acta Neurol Scand. 2010 Dec;122(6):418-24.


Apathy in drug-naïve patients with incident Parkinson’s disease: the Norwegian ParkWest study.
Pedersen KF, Alves G, Brønnick K, Aarsland D, Tysnes OB, Larsen JP.
J Neurol. 2010 Feb;257(2):217-23.


2009
Health state values during the first year of drug treatment in early-stage Parkinson’s disease: a prospective, population-based, cohort study.
Vossius C, Nilsen OB, Larsen JP.
Drugs Aging. 2009;26(11):973-80.


“Brain Atrophy and White Matter Hyperintensities in Early Parkinson’s Disease. The Norwegian ParkWest study”.
Dalaker TO, Larsen JP, Bergsland N, Beyer MK, Alves G, Dwyer MG, Tysnes OB, Benedict RH, Kelemen A, Bronnick K, Zivadinov R.
Mov Disord. 2009 Nov 15;24(15):2233-41.


White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson’s disease.
Dalaker TO, Larsen JP, Dwyer MG, Aarsland D, Beyer MK, Alves G, Bronnick K, Tysnes OB, Zivadinov R.
Neuroimage. 2009 Oct 1;47(4):2083-9.


The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson’s disease.
Aarsland D, Brønnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, Larsen JP.
J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):928-30.


Incidence of Parkinson’s disease in Norway: the Norwegian ParkWest study.
Alves G, Müller B, Herlofson K, HogenEsch I, Telstad W, Aarsland D, Tysnes OB, Larsen JP.
J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):851-7.


Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study.
Aarsland D, Brønnick K, Larsen JP, Tysnes OB, Alves G; Norwegian ParkWest Study Group.
Neurology. 2009 Mar 31;72(13):1121-6.

Det er stengt for kommentarer.